Additional hepatic (166)Ho-radioembolization in patients with neuroendocrine tumours treated with (177)Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)

BACKGROUND: Neuroendocrine tumours (NET) consist of a heterogeneous group of neoplasms with various organs of origin. At diagnosis 21% of the patients with a Grade 1 NET and 30% with a Grade 2 NET have distant metastases. Treatment with peptide receptor radionuclide therapy (PRRT) shows a high objec...

詳細記述

保存先:
書誌詳細
出版年:BMC Gastroenterol
主要な著者: Braat, Arthur J. A. T., Kwekkeboom, Dik J., Kam, Boen L. R., Teunissen, Jaap J. M., de Herder, Wouter W., Dreijerink, Koen M. A., van Rooij, Rob, Krijger, Gerard C., de Jong, Hugo W. A. M., van den Bosch, Maurice A. A. J., Lam, Marnix G. E. H.
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2018
主題:
Study Protocol
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6003090/
https://ncbi.nlm.nih.gov/pubmed/29902988
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-018-0817-8
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料